Good luck to BLUE, which has been the primary company I have relied on to indicate Price Change Parity with HGEN. I'm thinking your price change parity model will need an update after this FDA 'endorsement'. Preliminary congrats to those involved. https://www.statnews.com/2022/06/09/fda-advisers-endorse-bluebird-bio-gene-therapy-cerebral-adrenoleukodystrophy/